Screener
BridgeBio Pharma BBIO Reportable Segment — Income Tax Expense (Benefit)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net loss from equity method investments | (6,435) | (20,189) | (24,718) | (35,745) |
| Other income, net | 5,587 | 6,548 | 9,840 | 14,779 |
| Total other expense, net | (48,812) | (47,380) | (109,411) | (112,616) |
| Loss before income taxes | (155,891) | (181,658) | (322,446) | (351,266) |
| Provision for income taxes | — | 2,100 | — | 2,100 |
| Net loss | (155,891) | (183,758) | (322,446) | (353,366) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 3,675 | 1,855 | 6,187 | 4,041 |
| Segment net loss attributable to common stockholders of BridgeBio | $(152,216) | $(181,903) | $(316,259) | $(349,325) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — income tax expense (benefit)?
- BridgeBio Pharma (BBIO) reported reportable segment — income tax expense (benefit) of $0 in Q2 2026.
- How has BridgeBio Pharma's reportable segment — income tax expense (benefit) changed year-over-year?
- BridgeBio Pharma's reportable segment — income tax expense (benefit) decreased by 100.0% year-over-year, from $2.1M to $0.
- What does reportable segment — income tax expense (benefit) mean?
- This represents the total tax expense or benefit recognized by the company for the period, based on its taxable income or loss. It includes both current taxes payable and deferred tax adjustments. For companies with significant losses, this may appear as a tax benefit if the company can carry forward losses to offset future tax liabilities.
Ask your AI about BridgeBio Pharma's reportable segment — income tax expense (benefit).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude